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Abstract
Background: Poorly controlled asthma can lead to maternal and fetal complications. Despite the known risks of
poorly controlled asthma during pregnancy and the need for stepping up therapy when appropriate, there are
concerns that management is suboptimal in primary care.
Our objective was to investigate the management of asthma during pregnancy by general practitioners providing
shared maternity care.
Methods: A pre-piloted, anonymous mail survey was sent to all general practitioners (n = 842) involved in shared
maternity care at six maternity hospitals in Victoria, Australia. Respondents were asked about their perceived safety
of individual asthma medications during pregnancy. Approach to asthma management during pregnancy was
further explored using scenarios of pregnant women with stable and deteriorating asthma and poor medication
adherence.
Results: Inhaled corticosteroids (ICS) were perceived to be the safest and were the preferred preventive
medication in first trimester (74.1%), whilst leukotriene receptor antagonists were the least preferred (2.9%).
A quarter (25.8%) of respondents would stop or decrease patients’ ICS doses during pregnancy, even when their
asthma was well controlled by current therapy. In addition, 12.1% of respondents were not sure how to manage
deteriorating asthma during pregnancy and opted to refer to another health professional. Almost half the
respondents (48.9%) reported encountering medication nonadherence during pregnancy.
Conclusion: A lack of confidence and/or knowledge among general practitioners in managing deteriorating
asthma in pregnancy was observed despite a good understanding of the safety of asthma medications during
pregnancy, compliance with evidence-based guidelines in the selection of preventive medications, and self
reported good asthma knowledge.
Background
Optimal asthma control during pregnancy is vital for the
well-being of both mother and fetus. Poorly controlled
asthma increases the risk of pre-term birth, low birth
weight, cesarean section, stillbirth, intrauterine growth
restriction (IUGR), congenital malformations (e.g. ventricu-
lar and atrial septal defects, spina bifida), small for gesta-
tional age (SGA) infants, pre-eclampsia, chorioamnionitis,
low APGAR scores and gestational diabetes [1]. Fetal
hypoxia, also a result of poorly controlled asthma during
pregnancy, can lead to severe risks of neonatal respiratory
difficulties, fetal brain ischemia and cerebral palsy [2].
Moreover, fetal growth restriction has been associated with
the development of ischemic heart disease, hypertension,
and type 2 diabetes in adulthood [3-7]. Conversely, mater-
nal asthma that is well managed has not been associated
with any increased risk of complications [8,9]. A promptly
treated acute asthma attack during pregnancy is unlikely to
have a serious effect on the pregnancy, delivery, or the
health of the infant [10].
A decrease in the use of inhaled anti-inflammatory
agents (preventers) [inhaled corticosteroids (ICS)], symp-
tom controllers [long-acting beta agonists (LABA)] and
their combinations, but an increase in the use of relievers
[short-acting beta2 agonists (SABA)] during pregnancy has
been reported [11]. Chambers found that two in five
women discontinued or reduced their asthma medication
during pregnancy, leaving them at risk of uncontrolled
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have been shown to deliver offspring with lower mean
birth weight and length than women who did not [13].
Asthma management during pregnancy should follow
the stepwise management of asthma in adults. The British
Thoracic Society (BTS),[14] Global Initiative for Asthma
(GINA),[15] National Asthma Council of Australia (NAC)
[16] and National Heart, Lung and Blood Institute
(NHLBI)[17] recommend continuing pregnant women on
the same asthma therapy used prior to the pregnancy, if
their asthma is well controlled on that regimen. ICS are
the recommended first line agents for the treatment of
mild to moderate persistent asthma in most guidelines
except those of the American College of Obstetricians and
Gynecologists and the American College of Allergy,
Asthma and Immunology (ACOG & ACAAI),[18] which
recommend cromones ahead of ICS. A switch to budeso-
nide is recommended for women who are planning a preg-
nancy and already using an ICS, as it has more evidence
for safety during pregnancy [16].
Even though evidence is lacking for the safety of some
asthma medications during pregnancy, the risks of
uncontrolled asthma during pregnancy are very clear.
The authors recently conducted a systematic review of
the safety of regular preventive asthma medications dur-
ing pregnancy and reported some negative outcomes, but
also noted many factors confounding the trials [19]. It
was concluded that asthma preventive medications did
not cause poor perinatal outcomes. Health care providers
should not hesitate to increase doses or introduce addi-
tional medications as needed. Selection of preventive
medications for asthma management during pregnancy
should be based on an assessment of the risks and bene-
fits of medication use versus the risks of poorly con-
trolled asthma [19].
The main barrier reported when prescribing in preg-
nancy was access to current information about medication
effects on the foetus, due to lack of a single comprehensive
source of information, lack of time to access information
and rapidly outdated information [20]. Physicians’ and
obstetricians’ heavy reliance on the United States Food
and Drug Administration (FDA) pregnancy risk categories,
in combination with their reluctance to weigh risks versus
benefits of medication use in pregnancy in individual
patients, may be contributing to low prescribing rates dur-
ing pregnancy [20]. In one study from the United States,
pregnant asthmatic women were significantly less likely to
be prescribed oral steroids either in the emergency depart-
ment or on discharge from hospital than were non-preg-
nant asthmatic women [11]. The pregnant women were
also three times more likely than non-pregnant women to
report ongoing asthma exacerbations following hospital
discharge [11].
There is little information available regarding prescrib-
ing trends in pregnant women with asthma in primary
care. Despite the overwhelming consensus that pregnant
women with asthma should be rigorously managed, doc-
tors still under-prescribe. Due to the increased risk of
poor perinatal outcomes, pregnant asthmatic women are
recommended to have their asthma monitored at least
once a month and their therapy should be increased
when appropriate [17]. A study from Yale University
found that two-thirds of pregnant asthmatic women were
under-treated for asthma for three or more months of
pregnancy [12]. Pregnant women were concerned about
using steroids during pregnancy due to the perceived
effects on the unborn child. Two in five women said they
would be more likely to continue taking their asthma
medication during pregnancy if their prescriber had
recommended it, showing that prescribers have a vital
role in encouraging patient adherence to treatment
recommendations. Understanding the prescribing prac-
tices of physicians providing care to pregnant women
with asthma would provide valuable information to opti-
mise asthma management during pregnancy.
The objective of this study was to describe the manage-
ment of asthma during pregnancy by general practitioners,
with a view to informing initiatives for improving asthma
management, leading to improved maternal and fetal
outcomes.
Methods
An anonymous mail questionnaire was sent to all general
practitioners involved in shared maternity care (n = 842)
at six public maternity hospitals in Melbourne, Australia.
Shared care general practitioners are affiliated with one or
more maternity hospitals and review women with uncom-
plicated pregnancies regularly until delivery, rather than
having them attend maternity hospital out-patient antena-
tal clinics. Any general practitioner, who is accredited at a
maternity hospital as a Shared Maternity Care Affiliate,
can provide maternity shared care. To find out more
about this model of care and the accreditation processes,
please refer to http://www.health.vic.gov.au/maternitycare/
smcaguidelines.pdf
T h eq u e s t i o n n a i r ew a sd e s i g n e db yt h ea u t h o r su s i n g
items derived from the literature and discussion with
pharmacists and respiratory consultants. Face and content
validity was established through review by other experi-
enced researchers (n = 13) and general practitioners (n =
4). Minimal changes were made to the questionnaire
based on feedback. The final questionnaire (see additional
file 1) consisted of three sections: The first section had 9
items on demographics and the prescriber’s practice. The
second section asked respondents to rank their prefer-
ences for prescribing preventive asthma medication
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different asthma medications in each trimester. The third
section aimed to gauge respondents’ likely approach to
asthma management in pregnant women with the help of
two scenarios.
Initially, an explanatory letter, questionnaire and
reply-paid envelope were mailed by administrative staff
in charge of shared maternity care at each hospital. Due
to the anonymous nature of the survey, a blanket remin-
der letter, questionnaire and reply-paid envelope were
sent to all general practitioners six weeks later. As an
incentive, potential participants were advised that a
small donation would be made to the Asthma Founda-
tion of Victoria for each completed survey returned to
the investigators.
This study was endorsed by The Asthma Foundation
of Victoria and approved by the Monash University
Human Research Ethics Committee (Approval no.
CF10/2750 - 2010001557). Permission to contact partici-
pants was also sought from all participating institutions.
Statistical analysis
For a population of 850 general practitioners, 144
responses were required to ensure that the sample pro-
portions would be within ±5% of the true values with a
90% level of confidence. Data were analysed using
SPSS, version 19.0 (IBM, Somers, NY, USA, 2010). Chi
square and independent sample t-tests were performed
to investigate relationships between prescriber demo-
graphics and prescribing appropriateness, which was
identified for the vignettes according to global asthma
guidelines [14-18]. Significance level was set at
P < 0.05.
Results
A total of 176 questionnaires were returned (response
rate 20.9%); two were excluded from the analysis as
more than 20% of items were unanswered. Respon-
dents were mostly female (70.7%), practising in the
metropolitan region (84.5%) and had practised as gen-
eral practitioners for a median of 19 years. Approxi-
mately one-third of respondents had encountered
asthma in more than 10% of their pregnant patients.
The characteristics of respondents are shown in
Table 1.
ICS (74.1%) were the preferred preventive medication
for a pregnant woman with worsening asthma in the
first trimester, while leukotriene receptor antagonists
(LTRA) (2.9%) were the least preferred agents (Table 2).
At normal adult doses, ICS and beta2 agonists (short-
and long-acting) were perceived to be safe in all trime-
sters by the majority of respondents, while participants
had concerns about the safety of LTRA during all trime-
sters (Table 3).
Preferred management of asthma in pregnant women
Case vignette one part one (stable asthma in pregnancy)
A quarter of respondents would stop or reduce the dosage
of preventive asthma medication during pregnancy, even
though the patient’s asthma was well controlled on the
regimen prior to pregnancy (Table 4). A single agent ther-
apy rather than the combination was preferred by 20.3%
of respondents; but one respondent preferred to use ICS
Table 1 Demographics and practice information of
respondents (n = 174)*
Characteristic n (%)
Gender
Female 123 (70.7%)
Years of practice as a Family Practitioner
≤10years 23 (13.2%)
11-20years 63 (36.1%)
21-30years 63 (36.1%)
>30years 24 (13.7%)
Current practice location
Metropolitan 147 (84.5%)
Regional 15 (8.6%)
Rural 11 (6.3%)
Proportion of pregnant women cared for who have asthma
None 6 (3.4%)
<10% 108 (62.1%)
11-20% 52 (29.9%)
>20% 4 (2.3%)
Assistance with asthma management
None 120 (69.0%)
Practice nurse 34 (19.5%)
Asthma educator 4 (2.3%)
Both an asthma educator and practice nurse 3 (1.7%)
Perceived asthma knowledge
Poor 1 (0.6%)
Average 56 (32.2%)
Good 81 (46.6%)
Very good 35 (20.1%)
*Some numbers do not add up to 174 due to missing data
Table 2 Preferences for asthma preventive medication
use in pregnancy (n = 174)
Asthma preventive medication
class
n (%)
First
preference
Second
preference
Cromones 13 (7.5%) 22 (12.6%)
Leukotriene receptor antagonists
(LTRA)
5 (2.9%) 3 (1.7%)
Inhaled corticosteroids (ICS) 129 (74.1%) 24 (13.8%)
Long-acting beta2 agonists (LABA) 10 (5.7%) 11 (6.3%)
LABA/ICS combination 36 (20.7%) 73 (42.0%)
*Some numbers do not add up to 174 due to missing data
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salmeterol/fluticasone combination.
Case vignette one part two (deteriorating asthma in
pregnancy)
Only 62.6% of general practitioners opted to increase
the dosage of the current reg i m e no nd e t e r i o r a t i o no f
symptoms (Table 4). A few respondents (4.6%) decided
to continue the same regimen and not intervene, leaving
the patient at risk of uncontrolled asthma.
Patterns of prescribing and management had no asso-
ciation with the proportion of pregnant women treated
per year, years in practice, clinical setting, the availability
Table 3 Perceived safety of asthma medications during pregnancy in different trimesters (n = 174)
n (%)
First trimester Second trimester Third trimester
Drug Yes No Yes No Yes No
Cromones
Nedocromil 88 (50.9%) 41 (23.6%) 102 (59.0%) 22 (12.6%) 100 (57.8%) 23 (13.2%)
Sodium Cromoglycate 112 (64.4%) 29 (16.7%) 125 (71.8%) 15 (8.6%) 123 (70.7%) 17 (9.8%)
Inhaled corticosteroids
Beclomethasone 132 (75.9%) 23 (13.2%) 140 (80.5%) 16 (9.2%) 142 (81.6%) 15 (8.6%)
Budesonide 154 (88.5%) 6 (3.4%) 159 (91.4%) 3 (1.7%) 156 (89.7%) 3 (1.7%)
Ciclesonide 111 (63.8%) 31 (17.8%) 120 (69.0%) 23 (13.2%) 121 (69.5%) 21 (12.1%)
Fluticasone 133 (76.4%) 26 (14.9%) 144 (82.8%) 14 (8.0%) 147 (84.5%) 11 (6.3%)
Leukotriene receptor antagonists
Montelukast 47 (27.0%) 79 (45.4%) 60 (34.5%) 67 (38.5%) 59 (33.9%) 68 (39.1%)
Zafirlukast 29 (16.7%) 83 (47.7%) 40 (23.0%) 73 (42.0%) 40 (23.0%) 73 (42.0%)
Long-acting beta2 agonists
Eformoterol 101 (58.0%) 46 (26.4%) 120 (69.0%) 21 (12.1%) 121 (69.5%) 23 (13.2%)
Salmeterol 105 (60.3%) 44 (25.3%) 124 (71.3%) 20 (11.5%) 125 (71.8%) 22 (12.6%)
Oral corticosteroids
Prednisolone 141 (81.0%) 20 (11.5%) 151 (86.8%) 8 (4.6%) 149 (85.6%) 12 (6.9%)
Short-acting beta2 agonists
Salbutamol 167 (96.0%) 0 (0.0%) 164 (94.3%) 0 (0.0%) 164 (94.3%) 1 (0.6%)
Terbutaline 146 (83.9%) 5 (2.9%) 144 (82.8%) 4 (2.3%) 144 (82.8%) 6 (3.4%)
*Some numbers do not add up to 174 due to missing data
Table 4 Responses for case vignette one (n = 174)
Case vignette one:
A patient of yours has recently become pregnant. She has moderate asthma which is well controlled with salmeterol/fluticasone (250/25),
one puff twice daily, and salbutamol inhaler as required. She has no other medical conditions nor is she taking any other medications.
Part one (Stable asthma in pregnancy): She wonders whether she should continue these medications during pregnancy. What is your
intended action?
Responses for (i) n (%)
Continue her on the same medications 123 (70.7%)
Decrease her dose 43 (24.7%)
Refer 5 (2.9%)
Stop her medication 2 (1.2%)
Part two (deterioating asthma in pregnancy): A few weeks pass by and your patient returns. You notice that her asthma is deteriorating. She tells
you that she has been using her salbutamol inhaler more than three times per week. She has been compliant with the salmeterol/fluticasone and
has had no changes to her asthma medication regimen nor has she had any changes in lifestyle. What is your intended action?
Responses for (ii) n (%)
Increase her dose 116 (66.7%)
Refer 21 (12.1%)
Continue her on the same regimen and just monitor her asthma more closely 15 (8.6%)
Add another agent 10 (5.7%)
Decrease ICS regimen 9 (5.2%)
*Some numbers do not add up to 174 due to missing data
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ceived knowledge, or asthma management guidelines
followed (P values all greater than 0.05).
Case vignette two (nonadherent asthmatic pregnant
patient)
Over three quarters of respondents (82.2%) would rein-
force the need to use the eformoterol/budesonide combi-
nation by the 18 weeks pregnant woman with concerns
about the safety of this combination, given her history of
poor adherence (Table 5). Only two respondents chose
not to reinforce the need to adhere to the asthma regi-
men and a few (12.4%) chose to switch her to another
preventive medication that allowed more convenient
dosing.
Almost half of the respondents (48.9%) reported
encountering patients with poor adherence to preventive
asthma medications during pregnancy, putting them at
risk of complications. Strategies they employed for
improving adherence were: providing education on risks
associated with nonadherence to asthma medications
during pregnancy and poor asthma control (46.6%); pro-
viding education focusing on the safety of asthma medi-
cations during pregnancy (42.0%); organising regular
visits to monitor asthma control (36.2%); organising reg-
ular return visits to monitor adherence (27.6%); referral
to another health professional to monitor asthma con-
trol (8.6%) and referral to another health professional to
monitor adherence (4.6%).
Discussion
This study has shown a strong preference for ICS as
first line preventive therapy, which is the recommended
agent for pregnant women by most guidelines, including
the NAC guidelines [14-17]. In reporting perceived
safety of asthma medications in each trimester, ICS
were regarded as safe throughout pregnancy. Uncer-
tainty about the safety of LTRA throughout pregnancy
was evident. This could possibly be attributed to limited
safety data available on these newer medications and/or
prescribers’ lesser familiarity with these drugs.
It is comforting to know that prescribers are confident
addressing poor adherence when confronted with the
situation; all respondents listed strategies they have used
to improve adherence when noncompliance was
encountered. However, it is well known that patients do
not normally admit nonadherence and prescribers rarely
ask about adherence during consultations [21].
The majority of respondents opted to keep the woman
who recently became pregnant on the same asthma regi-
men as that prior to conception. However, a considerable
number of prescribers would either decrease or stop her
medication or refer her to another health professional,
even though her asthma was well controlled on a flutica-
sone/salmeterol regimen. Not surprisingly, more prescri-
bers opted to refer when her asthma started deteriorating.
Although referral was not an inappropriate action, the
case presented did not warrant referral according to the
Asthma Management Guidlelines[22] e.g. life threatening
asthma attacks, no response to therapy, need for frequent
courses of oral corticosteroids. This suggests a lack of con-
fidence and/or knowledge among general practitioners in
managing deteriorating asthma in pregnancy. Prescribers
apparently feel more comfortable referring these patients;
this is surprising in light of the fact that two-thirds of
respondents rated their asthma knowledge as good or very
good.
There were no differences between experienced and less
experienced prescribers in the appropriateness of asthma
medicines selected. This is evidence against the suggestion
that less experienced prescribers would be more likely to
under-prescribe and deem medications unsafe in preg-
nancy [23]. The proportion of pregnant women treated
per year, the clinical setting, support from a practice nurse
or asthma educator, perceived knowledge, and use of
Table 5 Responses for case vignette two (n = 174)
Case vignette two
One of your regular patients is 18 weeks pregnant and she asks you for a new prescription for salbutamol inhaler, as she is a health care
card holder and can get them cheaper on script. However, you notice that she got a script for salbutamol inhaler only last month. Upon
asking, you find out that she has stopped her budesonide/eformoterol inhaler because she fears it will harm her unborn child. Instead
she has been using her salbutamol inhaler more frequently to compensate. She has no other medical conditions nor is she taking any
other medications.
(i) Part one (nonadherent asthmatic pregnant patient): What is your intended action?*
*Participants could only tick one response for part one
Responses for (i) n (%)
Give script for salbutamol and reinforce the need to continue her preventive medication 143 (82.2%)
Give script for salbutamol but change her onto a different preventive medication 21 (12.4%)
Give script for salbutamol and refer 6 (3.5%)
Give script for salbutamol with no further questions 2 (1.2%)
Do not give the salbutamol script and refer patient 0 (0.0%)
*Some numbers do not add up to 174 due to missing data
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ing, but interpretation was limited by low sample size.
Some prescribers who said they followed a particular
guideline for asthma management still commented that
they would like more information regarding management
for this population. Morgan et al. found that the major
barriers to prescribing during pregnancy were lack of a
single comprehensive source of information, lack of time
and the fact that information gets outdated rapidly [23].
Limited data were available on the study population, but
most characteristics were in line with the general popula-
tion of Australian general practitioners, with the majority
practicing in the metropolitan area (84.5% vs. 71% as the
national average in 2009-10) [24]. No statistics are avail-
able on the characteristics of general practitioners involved
in shared maternity care. Our sample had a considerably
higher proportion of females than in the Australian popu-
lation of practicing general practitioners (70.7% vs 44%);
[24] shared maternity care may be more attractive to
female general practitioners. Our respondents were more
likely to have a nurse in their practice than reported in the
national statistics (21.2% vs 9.0%);[24] however, patients
attending nurse-run asthma clinics based in Australian
general practice did not show a greater improvement in
quality of life or lung function compared with those
receiving usual care [25].
Strengths and limitations
This study has provided information about general practi-
tioners’ likely management of asthma in pregnant women.
To the best of our knowledge, a survey of this nature has
not been previously reported. The study population com-
prised general practitioners providing shared maternity
care in affiliation with all the major Victorian maternity
hospitals, including the largest maternity hospital in Aus-
tralia. Our findings should make general practitioners
more aware of under utilization of preventive asthma
medications during pregnancy and improve the manage-
ment of women with asthma.
Our study had a modest response rate; however, this
level of response is typical for a postal survey directed to
general practitioners [26]. As the study was anonymous,
we were unable to follow up the non-respondents to
improve the response rate or to compare their characteris-
tics with those of the respondents. Responses were
received from general practitioners with a range of charac-
teristics; nevertheless, it is possible that the respondents
were more knowledgeable than their counterparts, in
which case the extent of poor practice observed would be
an underestimation. Thus, it is possible that the perception
of general practitioners and poor management of pregnant
asthmatic women could be underestimated. There is lim-
ited information on women’s experiences of asthma man-
agement during pregnancy; however, the authors are
currently conducting a qualitative study with pregnant
asthmatic women in each trimester and with varying
asthma severity to address this gap in the literature.
The authors are developing interventions and strate-
gies to promote awareness of poor asthma management
during pregnancy targeting both pregnant women with
asthma and their health professionals. These interven-
tions may take the form of educational modules that
can be used for continuing education of health care pro-
viders, or antenatal clinics specifically for pregnant
women with asthma.
Conclusion
Overall, general practitioners had a good understanding of
the safety of asthma medications during pregnancy, com-
plied with evidence-based guidelines in the selection of
preventive medications, and self reported good asthma
knowledge. Despite this, a lack of confidence and/or
knowledge among general practitioners in managing dete-
riorating asthma in pregnancy was observed. The findings
from this survey will inform the development of future
interventions and strategies to optimize asthma manage-
ment and outcomes in pregnant women.
Additional material
Additional file 1: Management of pregnant women with asthma
survey. This is the questionnaire used in our study to investigate
prescribing patterns and management strategies of pregnant women
with asthma by general practitioners. This survey was given to all our
participants and endorsed by the Asthma Foundation of Victoria.
List of abbreviations
ACOG & ACAAI: American College of Obstetricians and Gynecologists & the
American College of Allergy; Asthma and Immunology; APGAR: Named after
Dr Viginia Apgar (calculated by scores of the newborn’s activity; pulse;
grimace; appearance; respiration usually at 1 to 5 minutes after delivery);
BTS: British Thoracic Society; FDA: Food and Drug Administration; ICS:
Inhaled corticosteroids; IUGR: Intrauterine growth restriction; GINA: Global
Initiative for Asthma; LABA: Long-acting beta2 agonists; LTRA: Leukotriene
receptor antagonists; NAC: National Asthma Council of Australia; NHLBI:
National Heart; Lung and Blood Institute; SABA: Short-acting beta2 agonist;
SGA: Small for gestational age.
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